OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 TrialMyung‐Ju Ahn, D. Kim, Natasha B. Leighl et al.|Journal of Thoracic Oncology|2017Cited by 20